Artivion (NYSE:AORT) today announced positive results from a clinical trial for its On-X mechanical mitral valve replacement (MVR). Atlanta-based Artivion (formerly CryoLife) published results in The Annals of Thoracic Surgery. The Proact clinical trial, a multicenter, non-inferiority, two-arm study assessed whether, after an On-X MVR, patients could be safely managed with lower-intensity warfarin plus aspirin. […]
Artivion
CryoLife announces corporate rebrand, changes name to Artivion
CryoLife today announced that it is rebranding itself and changing its name to Artivion, effective immediately. The Kennesaw, Georgia-based company’s new name, derived from the words ‘aorta,’ ‘innovation’ and ‘vision,’ reflects its focus on creating devices to treat aortic disease. The company will also change its ticker symbol on the New York Stock Exchange to […]
